All In Biotech

Drug Trial Radar · NCT03960840

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Phase I/II, Open Label, Multicenter Study of Rapcabtagene Autoleucel in Adult Patients With CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

218

Actual

Start

Jun 26, 2019

Primary completion

Jun 30, 2027

Study completion Jul 24, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 23, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (3L+ DLBCL), adult acute lymphoblastic leukemia (ALL) and 1st Line High Risk Large B-Cell Lymphoma (1L HR LBCL).

Conditions

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Diffuse Large B-cell Lymphoma
  • Acute Lymphoblastic Leukemia
  • Large B-cell Lymphoma

Interventions

  • Rapcabtagene autoleucel single agentBiological

    Single infusion of rapcabtagene autoleucel

  • IbrutinibDrug

    Tablets or capsules for oral daily use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Dose recommendation: Incidence and nature of Dose Limiting Toxicities (Dose Escalation part only)Time frame: 28 days
  2. Phase 1: Safety: Incidence and severity of AEs and SAEs, including changes in laboratory values, ECG and vital signsTime frame: 24 months
  3. Phase 1: Tolerability: Ibrutinib dose modifications in the CLL/SLL armTime frame: 24 months
  4. Phase 1: Manufacture success: Number of patients infused with planned target doseTime frame: 24 months
  5. Phase 2: Complete Response Rate (CRR) as assessed by local InvestigatorTime frame: 24 months

Locations

37 sites in 8 countries. Site status is shown where the registry gives one.

  • University of California LA

    Los Angeles, California

  • Stanford University Medical Center

    Stanford, California

  • H Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Uni of Chi Medi Ctr Hema and Onco

    Chicago, Illinois

  • University of Kansas Cancer Center

    Westwood, Kansas

  • Mass Gen Hosp Cancer Center

    Boston, Massachusetts

  • University of Pennsylvania Clinical

    Philadelphia, Pennsylvania

  • Tennessee Oncology

    Nashville, Tennessee

  • St Davids South Austin Medical Ctr

    Austin, Texas

  • Uni Of TX MD Anderson Cancer Cntr

    Houston, Texas

  • Sarah Cannon Research Institute

    San Antonio, Texas

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Pierre-Bénite, France

  • Novartis Investigative Site

    Rennes, France

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, Germany

  • Novartis Investigative Site

    Leipzig, Saxony, Germany

  • Novartis Investigative Site

    Bergamo, BG, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Rozzano, MI, Italy

  • Novartis Investigative Site

    Fukuoka, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, Japan

  • Novartis Investigative Site

    Bunkyo Ku, Tokyo, Japan

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Córdoba, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Salamanca, Spain

  • Novartis Investigative Site

    Seville, Spain

  • Novartis Investigative Site

    Valencia, Spain

  • Novartis Investigative Site

    Badalona, Barcelona, Spain

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.